We also treated the K19‐C2mE GC mice with LZQ‐02‐023‐01, and found that 4‐week LZQ‐02‐023‐01 treatment could significantly reduce tumor burden and progression, as evidenced by decreased tumor size (Figure 6e), lower pathologic grade lesions and proliferation (Figure 6f; Figure S5p, Supporting Information). The gene discussed is KRT19; the disease is neoplasm.